Conatus Pharmaceuticals (CNAT) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts CNAT Hot Sheet
Join SI Premium – FREE
Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q3 EPS of ($0.31), $0.07 better than the analyst estimate of ($0.38).
For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
